The BC Centre for Excellence in HIV/AIDS (BC-CfE) firmly supports a move towards a more people-centred and evidence-based approach to drug policy, as pledged by the Honourable Health Minister Jane Philpott in her statement at the UN General Assembly Special Session (UNGASS) on drug policy last week.
The global War on Drugs has for years forced people who use drugs — and often their loved ones — into the shadows. This creates barriers to accessing health care and addiction treatment, making it harder for public health services, care providers and support groups to do their important job of connecting with those hardest to reach.
Treatment as Prevention (TasP), pioneered by the BC-CfE and implemented in British Columbia with support of the provincial government, has shown that bringing HIV services to those in need where they are at saves lives, prevents new infections and contributes to health care sustainability.
The roll-out of harm reduction, coupled with expanded HIV testing and treatment in B.C., has led to a 90 per cent decrease in AIDS cases and HIV mortality among HIV-infected IDUs in the province, and a 65 per cent decrease in the number of new HIV cases within this demographic, from 1994.
Since the opening of Insite in 2003, still North America’s first and only supervised injection facility, there have been no overdose deaths at the site. The number of fatal overdoses in the surrounding neighbourhood has decreased markedly, according to our BC-CfE research.
Our research has also found people who use safe injection sites are 30 per cent more likely to enter detox programs and 70 per cent less likely to share needles. The rest of the world is taking note as places like Ithaca, N.Y., and rural parts of Indiana are now considering implementing life-saving supervised injection facilities.
Our data clearly shows when pushed into alleys and hidden spaces, drug users might engage in unsafe behaviour to acquire or use drugs. Sharing needles can lead to the spread of some of the most costly health burdens of our time, including HIV and other blood-borne diseases such as infection with the hepatitis C virus (HCV). It is in this context we applaud Health Minister Philpott’s visionary pledge at the Special Session on Drug Policy at the last UNGASS.